SPTLC3 Is Essential for Complex I Activity and Contributes to Ischemic Cardiomyopathy.

Abstract

BACKGROUND:

Dysregulated metabolism of bioactive sphingolipids, including ceramides and sphingosine-1-phosphate, has been implicated in cardiovascular disease, although the specific species, disease contexts, and cellular roles are not completely understood. Sphingolipids are produced by the serine palmitoyltransferase enzyme, canonically composed of 2 subunits, SPTLC1 (serine palmitoyltransferase long chain base subunit 1) and SPTLC2 (serine palmitoyltransferase long chain base subunit 2). Noncanonical sphingolipids are produced by a more recently described subunit, SPTLC3 (serine palmitoyltransferase long chain base subunit 3).

METHODS:

The noncanonical (d16) and canonical (d18) sphingolipidome profiles in cardiac tissues of patients with end-stage ischemic cardiomyopathy and in mice with ischemic cardiomyopathy were analyzed by targeted lipidomics. Regulation of SPTLC3 by HIF1α under ischemic conditions was determined with chromatin immunoprecipitation. Transcriptomics, lipidomics, metabolomics, echocardiography, mitochondrial electron transport chain, mitochondrial membrane fluidity, and mitochondrial membrane potential were assessed in the cSPTLC3KO transgenic mice we generated. Furthermore, morphological and functional studies were performed on cSPTLC3KO mice subjected to permanent nonreperfused myocardial infarction.

RESULTS:

Herein, we report that SPTLC3 is induced in both human and mouse models of ischemic cardiomyopathy and leads to production of atypical sphingolipids bearing 16-carbon sphingoid bases, resulting in broad changes in cell sphingolipid composition. This induction is in part attributable to transcriptional regulation by HIF1α under ischemic conditions. Furthermore, cardiomyocyte-specific depletion of SPTLC3 in mice attenuates oxidative stress, fibrosis, and hypertrophy in chronic ischemia, and mice demonstrate improved cardiac function and increased survival along with increased ketone and glucose substrate metabolism utilization. Depletion of SPTLC3 mechanistically alters the membrane environment and subunit composition of mitochondrial complex I of the electron transport chain, decreasing its activity.

CONCLUSIONS:

Our findings suggest a novel essential role for SPTLC3 in electron transport chain function and a contribution to ischemic injury by regulating complex I activity.

• Authors: Anna Kovilakath, Adolfo G Mauro, Yolander Valentine, Frank Raucci, Maryam Jamil, Christiane Carter, Jeremy Thompson, Qun Chen, Beutner Gisela, Yang Yue, Jeremy Allegood, Xiaoxin X Wang, Jordan Dail, Teja Devarakonda, Komuraiah Myakala, Jolene J Windle, Mark A Subler, David Montefusco, Belinda Willard, Ali Javaheri, Tytus Bernas, Sushil K Mahata, Moshe Levi, Jinze Liu, George A Porter Jr, Edward J Lesnefsky, Fadi N Salloum, L Ashley Cowart
• Journal: Circulation (Circulation) (Apr 25 2024) ISSN: 1524-4539 [Electronic] United States
• PMID: 38660786 (Publication Type: Journal Article)